Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq:ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET.
Related news for (ELTX)
- Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
- Elicio Therapeutics Secures $10 Million in Financing
- Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
- Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
- Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer